抗可溶性肝抗原抗体阳性肝病患者的临床特征分析

肝脏 ›› 2021, Vol. 26 ›› Issue (7): 795-798.

抗可溶性肝抗原抗体阳性肝病患者的临床特征分析

钟艳丹, 俞海英, 郭银燕, 丁巧云, 曹兴国, 彭姗姗, 杨永峰

210003 江苏南京中医药大学附属南京医院(南京市第二医院)肝病免疫科

收稿日期:2020-11-25 出版日期:2021-07-31 发布日期:2021-09-02
通讯作者: 杨永峰,Email:yyf1979@163.com
基金资助:
江苏省青年医学人才项目(QNRC2016058)

Clinical characteristics of liver disease patients with positive anti SLA antibody

ZHONG Yan-dan, YU Hai-ying, GUO Yin-yan, DING Qiao-yun, CAO Xing-guo, PENG Shan-shan, YANG Yong-feng

Department of Hepatology and Immunology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine,Jiangsu 21003, China

Received:2020-11-25 Online:2021-07-31 Published:2021-09-02
Contact: YANG Yong-feng,Email:yyf1979@163.com

摘要/Abstract

摘要： 目的探讨AIH患者抗可溶性肝抗原抗体(抗SLA)阳性的临床意义。方法回顾性评估抗SLA在AIH和各种肝病中的检出率,并对抗SLA阳性AIH患者的临床特征、IAIHG-AIH评分、治疗反应和结局进行分析。对853例不同病因肝病患者进行血清抗SLA检测。采用免疫印迹法检测抗SLA。记录患者就诊时的一般特征和结果。结果 853例肝病患者中18例患者(2%)检测到抗SLA。其中AIH 11例,AIH/PBC 3例,PBC 2例,HBV 1例,DILI 1例。抗SLA在AIH患者中的检出率为6%(11/176)。11例抗SLA阳性的AIH患者接受免疫抑制治疗,出现生化学缓解,但其中有6例患者复发(停药后5例复发,缓解期1例复发)。结论抗SLA的检出率很低,但对AIH有较高的特异性。需要进一步的研究来证明抗SLA在AIH中的临床意义。

关键词: 自身抗体, 自身免疫性肝炎, 肝病

Abstract: Objective Anti SLA antibody is a specific serological marker of AIH. This study retrospectively evaluated the detection rate of anti SLA in AIH and various liver diseases, and analyzed the clinical characteristics, IAIHG-AIH score, treatment response and outcome of patients with anti SLA positive AIH. Methods Serum anti SLA was detected in 853 patients with liver diseases of different etiology. The presence of anti SLA was detected by Western blot. We recorded the general characteristics and test results of the patients. Results Anti SLA was detected in 18 (2%) of 853 liver disease patients. There were 11 cases of AIH (61.1%), 3 cases of AIH / PBC (16.7%), 2 cases of PBC (11.1%), 1 case of HBV (5.6%) and 1 case of DILI (5.6%). The detection rate of anti SLA in AIH patients was 6%. 11 patients with anti SLA positive AIH received immunosuppressive therapy and developed biochemical remission, but 6 of them relapsed (5 recurred after drug withdrawal and 1 relapsed in remission stage). Conclusion The detection rate of anti SLA is very low, but it has high specificity for AIH. Further studies are needed to prove the clinical significance of anti SLA in AIH.

Key words: Autoantibodies, Autoimmune hepatitis, Liver disease

钟艳丹, 俞海英, 郭银燕, 丁巧云, 曹兴国, 彭姗姗, 杨永峰. 抗可溶性肝抗原抗体阳性肝病患者的临床特征分析[J]. 肝脏, 2021, 26(7): 795-798.

ZHONG Yan-dan, YU Hai-ying, GUO Yin-yan, DING Qiao-yun, CAO Xing-guo, PENG Shan-shan, YANG Yong-feng. Clinical characteristics of liver disease patients with positive anti SLA antibody[J]. Chinese Hepatolgy, 2021, 26(7): 795-798.

参考文献

[1] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, 51: 2193-2213.
[2] Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 2008, 48: 169-176.
[3] Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci, 2011, 56: 545-554.
[4] Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology, 2002, 35: 658-664.
[5] Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology, 1998, 28: 296-301.
[6] Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol, 2010, 52: 745-758.
[7] Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology, 2010, 51: 660-678.
[8] Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol, 2010, 53: 372-384.
[9] Roberts EA, Schilsky ML, American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology, 2008, 47: 2089-2111.
[10] Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther, 2010, 32: 3-13.
[11] Manns M, Gerken G, Kyratsoulis A, et al. Characterization of a new subgroup of autoimmune chronic active hepatitis by auto-antibodies against a soluble liver antigen. Lancet, 1987, I: 292–294.
[12] Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut, 2002, 51: 259-264.
[13] Miyakawa H, Kawashima Y, Kitazawa E, et al. Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun, 2003, 21: 77-82.
[14] Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol, 2000, 33: 208-215.
[15] Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet, 2000, 355: 1510-1515.
[16] Eyraud V, Chazouilleres O, Ballot E, et al. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int, 2009, 29: 857-864.
[17] Vitozzi S, Djilali-Saiah I, Lapierre P, et al. Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity, 2002, 35: 485-492.
[18] Duclos-Vallée JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut, 2003, 52: 893-897.